Loading candles…
Zydus Lifesciences Ltd., formed in 1995 following the restructuring of the Zydus group and the establishment of Cadila Healthcare, is a global pharmaceutical company engaged in the discovery, development, manufacturing, and marketing of healthcare therapies. The company operates across three main segments: generic pharmaceuticals, branded pharmaceuticals, and consumer wellness. Its product offerings include Active Pharmaceutical Ingredients (APIs), finished formulations, and therapies in oncology, cardiology, and gastrointestinal health. Zydus Lifesciences maintains extensive research and development capabilities with a vertically integrated structure spanning from APIs to finished formulations. Operating within the pharmaceuticals and healthcare industries, the company serves a global market. Since its inception, the group's turnover expanded substantially from Rs. 250 crores in 1995 to over Rs. 14,253 crores in FY20.
| Type | Details | Date |
|---|---|---|
| Buyback | To consider buyback for equity shares | 19 May 2026 |
| Results - FY26 | To consider and approve the financial results for the period ended March 31, 2026 and dividend | 19 May 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended December 31, 2025 | 9 Feb 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended September 30, 2025 | 6 Nov 2025 |
| Fund Raising | To consider Fund Raising | 6 Nov 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended Jun 30, 2025 | 12 Aug 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended March 31, 2025 and dividend | 20 May 2025 |
Besseggen InfoTech LLP is a SEBI-registered stock broker (Reg. No. INZ000213450), member of NSE (90155 (Cash & F&O)) and BSE (6722 (Cash & F&O)). Investment in securities market are subject to market risks; read all related documents carefully before investing.